TrialNature communications2024

Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.

Qianqian Xin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.